Lyka Labs Ltd. Share Price

Overview

Lyka Labs Ltd. share price is currently ₹71.21, up by ₹0.15 (0.21%) from its previous closing price of ₹71.06. The share price has declined -11.69% over the past month and declined -25.16% over the past year. The stock's 52-week low and high are ₹43.60 and ₹100.03, respectively. Lyka Labs Ltd. has a market capitalisation of ₹ 290.00 Cr. The share price was last updated on 09 Oct 2026, 03:23 PM IST.

Lyka Labs Ltd.

LYKALABS

₹0.00

₹0.15

0.21%

Healthcare

₹0.00(%)1D

Updated: 09 Oct 2026, 03:23:34 pm IST

Market Data

Open Price

₹71.50

Prev. Close

₹71.06

₹69.53

Day Low

₹73.88

Day High

₹43.60

52 Week Low

₹100.03

52 Week High

HealthcarePharmaceuticals & Drugs

CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

-28.48

Sector PE

43.59

PB Ratio

2.76

Sector PB

5.76

EPS

-2.50

Dividend Yield

0.00

Today's Volume

25.330 K

5 Day Avg. Volume

26.376 K

PEG Ratio

0.13

Market Cap.

₹ 290.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Lyka Labs Ltd. 👋

Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company's R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →

Palak Jain

9 Jul • 2:41 PM · SEBI-Registered Analyst

!Lyka Labs Informs Shareholders Regarding FY 2024-25 Annual Report Access

!lykalab has sent letters to shareholders whose email addresses are not registered with the Company/Registrar & Transfer Agent/Depository Participants. The letter provides a weblink to access the Annual Report for FY 2024-25 from the company's website.